What the FDA labels say about taking them together
Erythromycin and vinblastine
Erythromycin's FDA label of August 1, 2024 names vinblastine in its drug interactions section, and vinblastine's label names erythromycin too. The erythromycin label: “… disopyramide, bromocriptine, rifabutin, quinidine methylprednisolone, cilostazol, and vinblastine.”
Check it at the source: the erythromycin FDA label on DailyMed (effective August 1, 2024, Teva Pharmaceuticals USA, Inc.); the vinblastine FDA label on DailyMed (effective April 15, 2025, Fresenius Kabi USA, LLC).
What does the erythromycin label say about vinblastine?
Erythromycin label, drug interactionsThere have been spontaneous or published reports of CYP3A based interactions of erythromycin with cyclosporine, carbamazepine, tacrolimus, alfentanil, disopyramide, rifabutin, quinidine, methyl-prednisolone, cilostazol, vinblastine, and bromocriptine.
Ery-Ped label (Azurity Pharmaceuticals, Inc. (formerly Arbor Pharmaceuticals), December 16, 2023), drug interactionsReduction of sildenafil dosage should be considered. (See Viagra package insert.) There have been spontaneous or published reports of CYP3A based interactions of erythromycin with cyclosporine, carbamazepine, tacrolimus, alfentanil, disopyramide, rifabutin, quinidine, methylprednisolone, cilostazol, vinblastine, and bromocriptine.
Erythromycin label (Dr. Reddy's Labratories Inc., September 25, 2025), drug interactionsReduction of sildenafil dosage should be considered. (See Viagra package insert.) There have been spontaneous or published reports of CYP3A based interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, alfentanil, disopyramide, bromocriptine, rifabutin, quinidine methylprednisolone, cilostazol, and vinblastine.
Source: FDA drug label (Ery-Ped, NDA050207), Azurity Pharmaceuticals, Inc. (formerly Arbor Pharmaceuticals), effective December 16, 2023 (SPL set 04775721-ab87-4b66-808c-d67a21032385), via openFDA
Source: FDA drug label (Erythromycin, NDA050536), Dr. Reddy's Labratories Inc., effective September 25, 2025 (SPL set a2dcb48a-212c-1b0c-ec35-ee2ade85847f), via openFDA
Source: FDA drug label (Erythromycin), Teva Pharmaceuticals USA, Inc., effective August 1, 2024 (SPL set 75a0bd5a-d09f-483b-bfd8-f8343b149eb2), via openFDA; the full label on DailyMed
What does the vinblastine label say about erythromycin?
Vinblastine label, drug interactionsEnhanced toxicity has been reported in patients receiving concomitant erythromycin (see ADVERSE REACTIONS ).
Source: FDA drug label (Vinblastine Sulfate), Fresenius Kabi USA, LLC, effective April 15, 2025 (SPL set f073b58e-56d6-4c8d-a2ce-b37719402d77), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Erythromycin | Vinblastine | |
|---|---|---|
| Labeled for | Bacterial infections, Acne | Leukemia, lymphoma and myeloma |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $1.96 per tablet 250 mg tablet | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once